Results 1 to 10 of about 18,311 (150)

Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma

Molecular Cancer, 2023
Background Circular RNAs (circRNAs) can be encapsulated into exosomes to participate in intercellular communication, affecting the malignant progression of a variety of tumors.
Zongqiang Hu, Gang Chen, Yingpeng Zhao, Hongqiang Gao, Lai-bang Li, Yan-feng Yin, Jie Jiang, Li Wang, Yuanyi Mang, Yang Gao, Shengning Zhang, Jianghua Ran, Li Li   +12 more
semanticscholar   +1 more source

Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1/Kyn/AHR axis

Gut, 2023
Objective Gut microbiota is a key player in dictating immunotherapy response. We aimed to explore the immunomodulatory effect of probiotic Lactobacillus gallinarum and its role in improving anti-programmed cell death protein 1 (PD1) efficacy against ...
W. Fong, Qing Li, Fenfen Ji, Wei Liang, H. C. Lau, Xing Kang, Weixin Liu, K. To, Zhong Zuo, Xiaoxing Li, Xiang Zhang, J. Sung, Jun Yu   +12 more
semanticscholar   +1 more source

Eubacterium rectale Improves the Efficacy of Anti-PD1 Immunotherapy in Melanoma via l-Serine-Mediated NK Cell Activation

Research, 2023
Natural killer (NK) cells, as key immune cells, play essential roles in tumor cell immune escape and immunotherapy. Accumulating evidence has demonstrated that the gut microbiota community affects the efficacy of anti-PD1 immunotherapy and that ...
Nian Liu, Lihui Chen, Mingjie Yan, Q. Tao, Jie Wu, J. Chen, C. Peng, Wei Zhang, Xiang Chen   +8 more
semanticscholar   +1 more source

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status

Oncoimmunology, 2023
Due to the high variance in response rates concerning anti-PD1 immunotherapy (IT), there is an unmet need to discover innovative biomarkers to predict immune checkpoint inhibitor (ICI)-efficacy.
D. Dora, B. Ligeti, T. Kovács, P. Revisnyei, G. Gálffy, E. Dulka, Dániel Krizsán, R. Kalcsevszki, Z. Megyesfalvi, B. Dome, G. Weiss, Z. Lohinai   +11 more
semanticscholar   +1 more source

CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

Journal of experimental & clinical cancer research : CR, 2023
Background Immune checkpoint blockade (ICB) has significantly prolonged survival of non-small cell lung cancer (NSCLC) patients, although most patients develop mechanisms of resistance.
B. Palermo, O. Franzese, G. Frisullo, L. D’Ambrosio, Mariangela Panetta, Giulia Campo, Daniel D’Andrea, Isabella Sperduti, F. De Nicola, F. Goeman, F. Gallina, Paolo Visca, F. Facciolo, P. Nisticò   +13 more
semanticscholar   +1 more source

Supplementation with α-ketoglutarate improved the efficacy of anti-PD1 melanoma treatment through epigenetic modulation of PD-L1

Cell Death and Disease, 2023
Patients with advanced melanoma have shown an improved outlook after anti-PD1 therapy, but the low response rate restricts clinical benefit; therefore, enhancing anti-PD1 therapeutic efficacy remains a major challenge.
Nian Liu, Jianglin Zhang, Ming Yan, Lihui Chen, Jie Wu, Qian Tao, B. Yan, Xiang Chen, C. Peng   +8 more
semanticscholar   +1 more source

Blockade of TNF-α/TNFR2 signalling suppresses colorectal cancer and enhances the efficacy of anti-PD1 immunotherapy by decreasing CCR8+T regulatory cells

Journal of Molecular Cell Biology, 2023
The enrichment of regulatory T cells (Tregs) in the tumour microenvironment (TME) has been recognized as one of the major factors in the initiation and development of resistance to immune checkpoint inhibitors.
Yixian Guo, Feng Xie, Xu Liu, Shouyu Ke, Jieqiong Chen, Yi Zhao, Ning Li, Zeyu Wang, Gang Yi, Yanying Shen, Dan Li, Chunchao Zhu, Zizhen Zhang, Gang Zhao, Hong Lu, Bin Li, Wenyi Zhao   +16 more
semanticscholar   +1 more source

Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma

Journal of experimental & clinical cancer research : CR, 2023
Background Clinical drawback in checkpoint inhibitors immunotherapy (ICI) of metastatic melanoma (MM) is monitoring clinical benefit. Soluble forms of PD1(sPD1) and PD-L1(sPD-L1) and extracellular vesicles (EVs) expressing PD1 and PD-L1 have recently ...
Simona Serratì, R. Di Fonte, L. Porcelli, S. De Summa, Ivana De Risi, L. Fucci, Eustachio Ruggieri, T. M. Marvulli, S. Strippoli, R. Fasano, Tania Rafaschieri, G. Guida, Michele Guida, A. Azzariti   +13 more
semanticscholar   +1 more source

De ideologische positie van Algemeen Nederlands in Vlaanderen

Taal en Tongval: Language Variation in the Low Countries, 2015
The ideological position of Standard Dutch in Flanders: the standard language ideology under pressure? In this paper, the results of a perception study in Flanders are reported. 80 informants were subjected to a qualitative interview, to gain insight in
Chloé Lybaert
doaj   +1 more source

NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model

Cancer Immunology and Immunotherapy, 2023
Radiotherapy (XRT), a well-known activator of the inflammasome and immune priming, is in part capable of reversing resistance to anti-PD1 treatment.
H. Barsoumian, K. He, Ethan Y. Hsu, G. Bertolet, D. Sezen, Yun Hu, T. Riad, M. Cortez, J. W. Welsh   +8 more
semanticscholar   +1 more source